AVBP - Company ID 0001868279
ArriVent BioPharma, Inc. trades as AVBP and has a market capitalization of $1.57 B, making it the #2330 largest US-listed company by market value. This page tracks ArriVent BioPharma, Inc. through 144 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-10
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-11 |
| Prospectus supplement | 424B5 | 2026-05-11 |
| Quarterly report | 10-Q | 2026-05-11 |
| Major company event | 8-K | 2026-05-11 |
| SCHEDULE 13G/A | - | 2026-05-06 |
| Annual report to shareholders | ARS | 2026-04-28 |
| Proxy materials | DEFA14A | 2026-04-28 |
| Proxy statement | DEF 14A | 2026-04-28 |
ArriVent BioPharma Reports First Quarter 2026 Financial Results | ArriVent Biopharma
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers | ArriVent Biopharma
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting | ArriVent Biopharma
ArriVent BioPharma Reports Full Year 2025 Financial Results | ArriVent Biopharma
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer | ArriVent Biopharma
The largest companies sharing ArriVent BioPharma, Inc.'s SEC industry classification (pharmaceutical preparations).
ArriVent BioPharma, Inc. (AVBP) has a market capitalization of $1.57 B as of 2026-07-10, ranking #2330 among US-listed companies.
In its latest fiscal year ArriVent BioPharma, Inc. reported a net loss of $166.31M.